Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …

Though recent reports link SARS-CoV-2 infections with hyper-inflammatory states in
children, most children experience no/mild symptoms, and hospitalization and mortality rates …

In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is
poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020 …

Antibodies are key immune effectors that confer protection against pathogenic threats. The
nature and longevity of the antibody response to SARS-CoV-2 infection are not well defined …

Background Understanding the longitudinal trajectory of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) antibodies is crucial for diagnosis of prior infection and …

Background This cross-sectional study aimed to track population-based SARS-CoV-2
antibody seropositivity duration across the United States using observational data from a …

Most subjects develop antibodies to SARS‐CoV‐2 following infection. In order to estimate
the duration of immunity induced by SARS‐CoV‐2 it is important to understand for how long …

Background The duration of humoral and T and B cell response after the infection of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear. Methods We …

Since the recent introduction of several viable vaccines for SARS-CoV-2, vaccination uptake
has become the key factor that will determine our success in containing the COVID-19 …